PI
NBIX icon

PEAK6 Investments’s Neurocrine Biosciences NBIX Stock Holding History

PEAK6 Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,277
Closed -$448K – 4499
2023
Q4 		$432K Buy
3,277
+1,305
+66% +$150K ﹤0.01% 2723
2023
Q3 		$222K Buy
+1,972
New +$208K ﹤0.01% 2996
2022
Q1 		– Sell
-5,070
Closed -$432K – 5714
2021
Q4 		$432K Sell
5,070
-2,791
-36% -$257K ﹤0.01% 3362
2021
Q3 		$754K Buy
+7,861
New +$743K ﹤0.01% 2868
2021
Q1 		– Sell
-8,319
Closed -$872K – 5309
2020
Q4 		$797K Sell
8,319
-3,711
-31% -$358K ﹤0.01% 2679
2020
Q3 		$1.16M Buy
12,030
+2,316
+24% +$268K ﹤0.01% 2138
2020
Q2 		$1.19M Sell
9,714
-6,337
-39% -$700K ﹤0.01% 1943
2020
Q1 		$1.39M Buy
16,051
+13,465
+521% +$1.32M 0.01% 1282
2019
Q4 		$278K Sell
2,586
-20,787
-89% -$2.18M ﹤0.01% 2347
2019
Q3 		$2.11M Sell
23,373
-5,109
-18% -$477K 0.01% 1241
2019
Q2 		$2.4M Sell
28,482
-23,576
-45% -$1.94M 0.02% 1147
2019
Q1 		$4.59M Buy
52,058
+575
+1% +$48.1K 0.03% 756
2018
Q4 		$3.68M Buy
+51,483
New +$4.93M 0.02% 834

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PEAK6 Investments's NBIX Position: Q1 2024 in Review

PEAK6 Investments sold out of Neurocrine Biosciences (NBIX) in Q1 2024, closing a stake of 3,277 shares — an estimated $448K sold.

PEAK6 Investments first reported a position in NBIX in Q4 2018 and held it in 13 quarters. The position peaked at $4.59M in Q1 2019. 589 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.

  • PEAK6 Investments reported no remaining Neurocrine Biosciences position as of Q1 2024 after selling out during the quarter.
  • PEAK6 Investments sold 3,277 Neurocrine Biosciences shares in Q1 2024, an estimated $448K.
  • PEAK6 Investments first reported a position in Neurocrine Biosciences in Q4 2018 and held it in 13 quarters.
  • PEAK6 Investments's Neurocrine Biosciences position peaked at $4.59M in Q1 2019.
  • 589 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.

Based on PEAK6 Investments's 13F filing for Q1 2024, filed 14 May 2024.